Caribou Biosciences (CRBU) Retained Earnings (2021 - 2026)
Caribou Biosciences (CRBU) reported Retained Earnings of -$23000.0 for Q1 2026, up 100.0% year-over-year from -$11500.3 in Q1 2025, and down 122.33% on a QoQ basis from $103000.0 in Q4 2025.
Caribou Biosciences (CRBU) has 6 years of Retained Earnings data on file, last reported at -$23000.0 in Q1 2026.
- Quarterly Retained Earnings rose 100.0% year-over-year to -$23000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23000.0 (up 100.0% YoY) and the FY2025 annual result came in at $103000.0, down 59.61% from the prior year.
- Retained Earnings fell to -$23000.0 in Q1 2026 per CRBU's latest filing, from $103000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $255000.0 in Q4 2024 and bottomed at -$570.0 million in Q3 2025.
- The 5-year median for Retained Earnings is -$197.2 million (2022), against an average of -$220.5 million.
- Peak annual rise in Retained Earnings reached 100.09% in 2024, while the deepest fall reached 46546.44% in 2024.
- Tracing CRBU's Retained Earnings over 5 years: stood at -$197.2 million in 2022, then slumped by 51.76% to -$299.3 million in 2023, then soared by 100.09% to $255000.0 in 2024, then slumped by 59.61% to $103000.0 in 2025, then plunged by 122.33% to -$23000.0 in 2026.
- Per Business Quant, the three latest CRBU Retained Earnings figures stand at -$23000.0 (Q1 2026), $103000.0 (Q4 2025), and -$570.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | -23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23,000.00 |
| Dec 31, 2025 | 103,000.00 |
| Sep 30, 2025 | -570.03 Mn |
| Jun 30, 2025 | -542.50 Mn |
| Mar 31, 2025 | -488.38 Mn |
| Dec 31, 2024 | 255,000.00 |
| Sep 30, 2024 | -412.90 Mn |
| Jun 30, 2024 | -378.22 Mn |
| Mar 31, 2024 | -340.52 Mn |
| Dec 31, 2023 | -299.29 Mn |
| Sep 30, 2023 | -981,000.00 |
| Jun 30, 2023 | -254.80 Mn |
| Mar 31, 2023 | -730,000.00 |
| Dec 31, 2022 | -197.22 Mn |
| Sep 30, 2022 | -2.04 Mn |
| Jun 30, 2022 | -143.60 Mn |
| Mar 31, 2022 | -116.90 Mn |
| Dec 31, 2021 | -97.79 Mn |
| Sep 30, 2021 | -79.32 Mn |
| Jun 30, 2021 | -58.34 Mn |